Literature DB >> 3139405

Hyperphosphorylation of N-60, a protein structurally and immunologically related to nucleolin after tumour-promoter treatment.

O G Issinger1, T Martin, W W Richter, M Olson, H Fujiki.   

Abstract

Okadaic acid, a non-TPA-type tumour promoter, induces hyperphosphorylation of a 60-kd protein in primary human fibroblasts. Treatment with TPA-type tumour promoters (e.g. TPA and teleocidin) did not cause this hyperphosphorylation. Phosphorylation of this protein was not seen at times earlier than 90 min after the addition of 75 ng/ml okadaic acid to the proliferating cell cultures. The presence of inhibitors such as actinomycin D and cycloheximide, did not significantly influence the level of hyperphosphorylation induced by okadaic acid treatment. By immunoblotting using an antibody anti-nucleolin, the 60-kd protein was identified as a fragment of nucleolar protein, nucleolin. Similarly, antibodies against the 60-kd protein cross-reacted with nucleolin. Furthermore peptide mapping, using staphylococcal V8 protease, showed that the 60-kd protein phosphorylated by casein kinase II in vitro and the okadaic-acid-induced hyperphosphorylated 60-kd protein exhibited identical phosphopeptide maps, indicating that there is also structural relatedness between N-60 and nucleolin. Hyperphosphorylation of the nucleolin fragment (N-60) was suppressed by anti-tumour promoter retinoic acid.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139405      PMCID: PMC457145          DOI: 10.1002/j.1460-2075.1988.tb02988.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  36 in total

1.  Studies on the mechanism of skin tumor promotion.

Authors:  H Hennings; R K Boutwell
Journal:  Cancer Res       Date:  1970-02       Impact factor: 12.701

2.  Control of macromolecular synthesis in proliferating and resting Syrian hamster cells in monolayer culture. I. Ribosome function.

Authors:  C P Stanners; H Becker
Journal:  J Cell Physiol       Date:  1971-02       Impact factor: 6.384

3.  Induction of a substrate for casein kinase II during lymphocyte mitogenesis.

Authors:  R L Geahlen; M L Harrison
Journal:  Biochim Biophys Acta       Date:  1984-06-19

4.  Localization of phosphoprotein C23 in nucleoli by immunological methods.

Authors:  M O Olson; K Guetzow; H Busch
Journal:  Exp Cell Res       Date:  1981-10       Impact factor: 3.905

5.  Role of phosphorylation on the maturation pathways of a 100 kDa nucleolar protein.

Authors:  H Bourbon; B Bugler; M Caizergues-Ferrer; F Amalric
Journal:  FEBS Lett       Date:  1983-05-08       Impact factor: 4.124

6.  Localization of phosphorylated highly acidic regions in the NH2-terminal half of nucleolar protein C23.

Authors:  S V Rao; M D Mamrack; M O Olson
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

7.  Interrelations between the maturation of a 100 kDa nucleolar protein and pre rRNA synthesis in CHO cells.

Authors:  G Bouche; M Caizergues-Ferrer; B Bugler; F Amalric
Journal:  Nucleic Acids Res       Date:  1984-04-11       Impact factor: 16.971

8.  A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots.

Authors:  M S Blake; K H Johnston; G J Russell-Jones; E C Gotschlich
Journal:  Anal Biochem       Date:  1984-01       Impact factor: 3.365

9.  Protective effect of cAMP on tumor promoter-mediated inhibition of cell-cell communication.

Authors:  Y Kanno; T Enomoto; Y Shiba; H Yamasaki
Journal:  Exp Cell Res       Date:  1984-05       Impact factor: 3.905

10.  Influence of hyperthermia on the phosphorylation of ribosomal protein S6 from human skin fibroblasts and meningioma cells.

Authors:  W W Richter; K D Zang; O G Issinger
Journal:  FEBS Lett       Date:  1983-03-21       Impact factor: 4.124

View more
  9 in total

1.  Regulation of collagenase gene expression by okadaic acid, an inhibitor of protein phosphatases.

Authors:  S J Kim; R Lafyatis; K Y Kim; P Angel; H Fujiki; M Karin; M B Sporn; A B Roberts
Journal:  Cell Regul       Date:  1990-02

2.  Nucleolin from the multiple nucleoli of amphibian oocyte nuclei.

Authors:  P J DiMario; J G Gall
Journal:  Chromosoma       Date:  1990-04       Impact factor: 4.316

3.  Effects of okadaic acid on cytosolic calcium concentrations and on contractions of the porcine coronary artery.

Authors:  K Hirano; H Kanaide; M Nakamura
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

4.  The carboxy-terminal fragment of nucleolin interacts with the nucleocapsid domain of retroviral gag proteins and inhibits virion assembly.

Authors:  E Bacharach; J Gonsky; K Alin; M Orlova; S P Goff
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Flat reversion by okadaic acid of raf and ret-II transformants.

Authors:  R Sakai; I Ikeda; H Kitani; H Fujiki; F Takaku; U Rapp; T Sugimura; M Nagao
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

6.  Okadaic acid. Protein phosphatase inhibition and muscle contractile effects.

Authors:  A Takai
Journal:  J Muscle Res Cell Motil       Date:  1988-12       Impact factor: 2.698

7.  Okadaic acid, a potent inhibitor of type 1 and type 2A protein phosphatases, activates cdc2/H1 kinase and transiently induces a premature mitosis-like state in BHK21 cells.

Authors:  K Yamashita; H Yasuda; J Pines; K Yasumoto; H Nishitani; M Ohtsubo; T Hunter; T Sugimura; T Nishimoto
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

8.  Mechanisms of action of okadaic acid class tumor promoters on mouse skin.

Authors:  H Fujiki; M Suganuma; S Yoshizawa; S Nishiwaki; B Winyar; T Sugimura
Journal:  Environ Health Perspect       Date:  1991-06       Impact factor: 9.031

9.  Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication.

Authors:  Iva Ugrinova; Karine Monier; Corinne Ivaldi; Marc Thiry; Sébastien Storck; Fabien Mongelard; Philippe Bouvet
Journal:  BMC Mol Biol       Date:  2007-08-10       Impact factor: 2.946

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.